Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Published byBenedict Kennedy Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large."— Presentation transcript:

1 Figure 1. Progression-free survival and overall survival for FL/DLBCL patients.
From: Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma Ann Oncol. 2017;28(11): doi: /annonc/mdx407 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please

2 Figure 2. Progression free survival (PFS) (A) and overall survival (OS) (B) according to histological grade of follicular lymphoma (FL), PFS (C) and OS (D) according to the percentage of diffuse large B-cell lymphoma (DLBCL) component and PFS (E) and OS (F) according to the cell of origin in FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma Ann Oncol. 2017;28(11): doi: /annonc/mdx407 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please

3 Figure 3. Progression-free survival (A) and overall survival (B) for follicular lymphoma (FL) grades 1-3a, FL/diffuse large B-cell lymphoma (DLBCL) and DLBCL groups. From: Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma Ann Oncol. 2017;28(11): doi: /annonc/mdx407 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please

Download ppt "Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large."

Similar presentations

From: An open day in the metric space

From: An open day in the metric space
Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.
Fig. 1 Flow chart of the COBRA-light trial and its extension study

Fig. 1 Flow chart of the COBRA-light trial and its extension study
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.

Figure 1. Programme provisions, eligibility, evaluation period and geographical coverage of programme over time From: Impact evaluation of free delivery.
Error bars represent the mean (s.e.).

Error bars represent the mean (s.e.).
Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p

Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p
pSS: primary SS; Scl: scleroderma.

pSS: primary SS; Scl: scleroderma.
Figure 3. Examples of tweets classified as ridicule.

Figure 3. Examples of tweets classified as ridicule.
Figure 1. Selection of papers.

Figure 1. Selection of papers.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser
Figure 1 (A) Chest computed tomography scans of the patient

Figure 1 (A) Chest computed tomography scans of the patient
Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. (A) Sézary syndrome patient before treatment

Similar presentations

Ads by Google